Friday, June 18, 2021, 0900 – 0930 AM (ET)
Integrating MammaPrint® and BluePrint® Molecular Subtyping into Treatment Planning for Patients with Early-Stage Breast Cancer

Speaker

Henry J. Conter BESc MD MSF MSc
Adjunct Professor of Medicine
University of Western Ontario
Schulich School of Medicine & Dentistry
Medical Oncologist, William Osler Health System

Learning Objectives

• Review MammaPrint and BluePrint’s clinical utility for patients with breast cancer
• Discuss the impact of knowing the functional molecular subtype in the neoadjuvant or adjuvant setting
• Case based review and real-world utilization impact of MammaPrint + BluePrint genomic testing

Friday, June 18, 2021, 0930 – 1000 AM (ET)
Maximizing Precision in the Treatment of Early Stage Node Positive Breast Cancer – A Case Based Discussion

Join presenters as they apply results from the recent RxPONDER trial in early-stage node positive breast cancer to clinical practice.

Faculty

Jean-Francois Boileau MD MSc FRCSC
Surgical Oncologist, Jewish General Hospital Segal Cancer Centre
Associate Professor Surgery and Oncology, McGill University
Director JGH Breast Clinical Trials Group

Kasia Jerzak MD MSc FRCPC
Medical Oncologist, Sunnybrook Odette Cancer Centre
Associate Scientist, Sunnybrook Research Institute
Assistant Professor
Department of Medicine, Division of Oncology
Temerty Faculty of Medicine, University of Toronto/small>